



09-20-04

PATENT  
678503-2007.1

IFW

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : KOROKHOV et al.  
Serial No. : 10/624,218  
For : ADENOVIRAL VECTOR INCORPORATING ZIPPER  
PEPTIDE-MODIFIED FIBER PROTEIN AND USES  
THEREOF  
Filed : July 22, 2003  
Examiner : To Be Assigned  
Art Unit : 1646

745 Fifth Avenue  
New York, NY 10151

**EXPRESS MAIL**

Mailing Label Number:

Date of Deposit:

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressec" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Adam Shmelev  
(Typed or printed name of person mailing paper or fee)

A. Shmelev  
(Signature of person mailing paper or fee)

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97(b)(3) AND 1.98**

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

The Examiner's attention is respectfully drawn to the enclosed documents listed on the accompanying PTO Form 1449.


Pursuant to 37 CFR §1.97(b)(3), Applicants request the Examiner to consider this Information Disclosure Statement, and to make of record the documents cited on the

accompanying PTO form 1449 and that a copy of Form PTO-1449 be initialed by the Examiner and returned to the undersigned.

The filing of this Information Disclosure Statement is not an admission that the documents identified herein constitute prior art to the present application.

It is believed that no fees are required by the instant submission as it is prior to receipt of the first Office Action on the merits. However, if any fees are required, or if any overpayment has been made, please charge Deposit Acct. No. 50-0320.


Respectfully submitted,  
FROMMER LAWRENCE & HAUG LLP

By:   
Thomas J. Kowalski  
Reg. No. 32,147  
Deborah L. Lu  
Reg. No. 50,940  
Tel. No. (212) 588-0800  
Fax No. (212) 588-0500

Encs. PTO Form 1449  
References (65)

Based on Form PTO-1449  
(3/90)

LIST OF REFERENCES CITED BY APPLICANT  
(Use several sheets if necessary)



ATTY. DOCKET NO.

678503-2007.1

SERIAL NO.

10/624,218

APPLICANT

Korokhov et al.

FILING DATE

July 22, 2003

GROUP

1646

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,210,946	04/03/2001	Curiel et al.			
	6,284,742	09/04/2001	Curiel et al.			

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

		Amtdt et al.; A Heterodimeric Coiled-coil Peptide Pair Selected in Vivo from a Designed Library-versus-Library Ensemble; J. Mol. Biol. (2000) 295, 627-639.
		Asada-Mikami et al.; Efficient Gene Transduction by RGD-fiber Modified Recombinant Adenovirus into Dendritic Cells; Jpn. J. Cancer Res. 92, 321-327, March 2001.
		Banchereau & Steinman; Dendritic cells and the control of immunity; NATURE, Vol. 392, 19 March 1988; pgs. 245-252.
		Belousova et al., Generation of recombinant adenoviral vectors containing fiber proteins with extended HI-loops; Molecular Therapy vol. 3, no. 5, May 2001, S168
		Belousova et al., Genetically Targeted Adenovirus Vector Directed to CD40-Expressing Cells; Journal of Virology; Nov. 2003; Vol. 77, No. 21; pgs 11367-11377.
		Bewig & Schmidt; Accelerated Titering of Adenoviruses; Biotechniques, Vol. 28, No. 5 (2000)
		Bocchia et al., Antitumor vaccination: where we stand; Haematologica 2000; 85:1172-1206
		Boon et al., Tumor Antigens Recognized By T Lymphocytes, Thierry Boon, Jean-Charles Cerottini, Benoît Van den Eynde, Pierre van der Bruggen, Aline Van Pel; Annu. Rev. Immunol. 1994; 12:337-65.
		Brand et al.; Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors; Cancer Gene Therapy, Vol. 4, No. 1, 1997, pp. 9-16.
		Brossart et al.; Virus-Mediated Delivery of Antigens Epitopes into Dendritic Cells as a Means to Induce CTL; The Journal of Immunology, 1997, 158:3270-3276.
		Correale et al., In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived From Prostate-Specific Antigen; Journal of the National Cancer Institute; Vol. 89, No. 4, February 19, 1997.
		Coulie et al., Antigens recognized by T-lymphocytes on human tumours; Biochemical Society Transactions, Vol. 25.
		Dietz and Vuk-Pavlović High Efficiency Adenovirus-Mediated Gene Transfer to Human Dendritic Cells; Blood, Vol. 91, No. 2 (January 15): pp. 392-398.
		Dmitriev et al.; An Adenovirus Vector with Genetically Modified Fibers Demonstrates Expanded Tropism via Utilization of a Coxsackievirus and Adenovirus Receptor-Independent Cell Entry Mechanism; Journal of Virology, Dec. 1988, pgs. 9706-9713.
		Dmitriev et al.; Ectodomain of Coxsackievirus and Adenovirus Receptor Genetically Fused to Epidermal Growth Factor Mediates Adenovirus Targeting to Epidermal Growth Factor Receptor-Positive Cells; Journal of Virology, Aug. 2000, pp. 6875-6884.

		Douglas et al.; A system for the propagation of adenoviral vectors with genetically modified receptor specificities; Nature Biotechnology, May 1999, Vol. 17, pp. 470-474.
		Fong and Engleman; Dendritic Cells in Cancer Immunotherapy; Annu. Rev. Immunol. 2000, 18:245-273.
		Freimuth; A Human Cell Line Selected for Resistance to Adenovirus Infection Has Reduced Levels of the Virus Receptor; Journal of Virology, June 1996, pp. 4081-4085.
		Gong et al.; Reversal of tolerance to human MUC1 antigen in MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells; Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 6279-6283, May 1998
		Hodges; De novo design of $\alpha$ -helical proteins: basic research to medical applications; Biochem. Cell Biol. 74: 133-154 (1996)
		Hong & Engler; Domains Required for Assembly of Adenovirus Type 2 Fiber Trimers; Journal of Virology, Oct. 1996, p. 7071-7078.
		Hsu et al.; Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells; Nature Medicine, Volume 2, Number 1, January 1996, pp. 52-58.
		Hurst; Transcription Factors 1: bZIP proteins; Protein Profile, Volume 2, Issue 2, pp. 105-168.
		Kaplan et al.; Induction of Antitumor Immunity with Dendritic Cells Transduced with Adenovirus Vector-Encoding Endogenous Tumor-Associated Antigens; The Journal of Immunology, April 30, 1999, pp. 699-707.
		Katz et al.; Green Fluorescent Protein Labeling of Cytoskeletal Structures—Novel Targeting Approach Based on Leucine Zippers; BioTechniques, Vol. 25, No. 2 (1998), pp. 298-303.
		Krasnykh et al.; Generation of Recombinant Adenovirus Vectors with Modified Fibers for Altering Viral Tropism; Journal of Virology, Oct. 1996, pp. 6839-6846.
		Krasnykh et al.; Characterization of an Adenovirus Vector Containing a Heterologous Peptide Epitope in the HI Loop of the Fiber Knob; Journal of Virology, Mar. 1998, pp. 1844-1852.
		Krasnykh et al.; Genetic Targeting of an Adenovirus Vector via Replacement of the Fiber Protein with the Phage T4 Fibrin; Journal of Virology, May 2001, pp. 4176-4183.
		Kugler et al.; Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids; Nature Medicine, Volume 6, Number 3, March 2000, pp. 332-336.
		Kwak et al.; Induction of Immune Responses in Patients with B-Cell Lymphoma Against the Surface-Immunoglobulin Idiotypic Expressed by Their Tumors; The New England Journal of Medicine, Vol. 327, No. 17, pp. 1209-1215.
		Lee et al.; Phenotype, Function, and In Vivo Migration and Survival of Allogeneic Dendritic Cell Progenitors Genetically Engineered to Express TGF- $\beta$ ; Transplantation, Vol. 66, pp. 1810-1817, No. 12, December 27, 1998.
		Lozier et al.; Adenovirus-Mediated Expression of Human Coagulation Factor IX in the Rhesus Macaque Is Associated With Dose-Limiting Toxicity; Blood, Vol. 94, No. 12, December 15, 1999, pp. 3968-3975.
		Mathias et al.; Interactions of Soluble Recombinant Integrin $\alpha\beta 5$ with Human Adenoviruses; Journal of Virology, Nov. 1998, pp. 8669-8675.
		Mayordomo et al.; Bone Marrow-Derived Dendritic Cells Serve as Potent Adjuvants for Peptide-Based Antitumor Vaccines; Stem Cells 1997; 15:94-103
		Michael et al.; Addition of a short peptide ligand to the adenovirus fiber protein; Gene Therapy (1995) 2, 660-668.
		Mittereder et al.; Evaluation of the Concentration and Bioactivity of Adenovirus Vectors for Gene Therapy; Journal of Virology, Nov. 1996, pp. 7498-7509.
		Moll et al.; Designed heterodimerizing leucine zippers with a range of pIs and stabilities up to $10^{-15}$ M; Protein Science (2001), 10:649-655.
		Morris et al.; Incorporation of an Isoleucine Zipper Motif Enhances the Biological Activity of Soluble CD40L (CD154); The Journal of Biological Chemistry, Vol. 274, No. 1, Issue of January 1, pp. 418-423, 1999.
		Murphy et al.; Phase II Prostate Cancer Vaccine Trial: Report of a Study Involving 37 Patients with Disease Recurrence Following Primary Treatment; The Prostate 39:54-59 (1999)
		Nestle et al.; Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells; Nature Medicine, Volume 4, Number 3, March 1998, pp. 328-332.
		Okada et al.; Efficient Gene Delivery into dendritic Cells by Fiber-Mutant Adenovirus Vectors; Biochemical and Biophysical Research Communications 282, 173-179 (2001).
		O'Neal et al.; Toxicological Comparison of E2a-Deleted and First-Generation Adenoviral Vectors Expressing $\alpha_1$ -Antitrypsin after Systemic Delivery; Human Gene Therapy 9:1587-1598 (July 20, 1998).
		O'Neal et al.; Toxicity Associated with Repeated Administration of First-Generation Adenovirus Vectors Does Not Occur with a Helper-Dependent Vector; Molecular Medicine 6(3): 179-195, 2000.
		Pardoll; Cancer vaccines; Immunology Today, Vol. 14, No. 6, 1993, pp. 310-316.
		Parrot & Barry; Metabolically Biotinylated Gene Therapy Vectors; Molecular Therapy vol. 3, no. 5, May 2001, S165
		Pereboev et al.; Phage Display of Adenovirus Type 5 Fiber Knob as a Tool for Specific Ligand Selection and Validation, Journal of Virology, Aug. 2001, pp. 7107-7113.

			Pullen et al.; High-Affinity Interactions of Tumor Necrosis Factor Receptor-Associated Factors (TRAFs) and CD40 Require TRAF Trimerization and CD40 Multimerization; Biochemistry, 1999, 38, 10168-10177.
			Rea et al.; Adenoviruses Activate Human Dendritic Cells without Polarization toward a T-Helper Type 1-Inducing Subset; Journal of Virology, jDec. 1999, pp. 10245-10253.
			Robbins & Kawakami; Human tumor antigens recognized by T cells. Current Opinion in Immunology 1996, 8:628-636.
			Song et al.; Dendritic Cells Genetically Modified with an Adenovirus Vector Encoding the cDNA for a Model Antigen Induce Protective and Therapeutic Antitumor Immunity; Journal Exp. Medicine, Volume 186, Number 8, October 20, 1997 1247-1256.
			Specht et al.; Dendritic Cells Retrovirally Transduced with a Model Antigen Gene are Therapeutically Effective against Established Pulmonary Metastases; The Journal of Experimental Medicine, Volume 186, Number 8, October 20, 1997 1213-1221.
			Su et al.; CD154 Variant Lacking Tumor Necrosis Factor Homologous Domain Inhibits Cell Surface Expression of Wild-type Protein; The Journal of Biological Chemistry, Vol. 276, No. 3, Issue of January 19, pp. 1673-1676, 2001.
			Tillman et al.; Maturation of Dendritic Cells Accompanies High-Efficiency Gene Transfer by a CD40-Targeted Adenoviral Vector; The Journal of Immunology, 1999.
			Tillman et al.; Adenoviral Vectors Targeted to CD40 Enhance the Efficacy of Dendritic Cell-based Vaccination against Human Papillomavirus 16-induced Tumor Cells in a Murine Model; Cancer Research 60, 5456-5463, October 1, 2000.
			Timmerman & Levy; Dendritic Cell Vaccines for Cancer Immunotherapy; Ammu. Rev. Med. 1999, 50:507-29.
			Tjoa et al.; Presentation of Prostate Tumor Antigens by Dendritic Cells Stimulates T-Cell Proliferation and Cytotoxicity; The Prostate 28:65-69 (1996)
			Tsang et al.; Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes from Patients Immunized with Recombinant Vaccinia-CEA Vaccine; Journal of National Cancer Institute, Vol. 87, No. 13, July 5, 1995.
			Von Seggern et al.; Complementation of a fibre mutant adenovirus by packaging cell lines stably expressing the adenovirus type 5 fibre protein; Journal of General Virology (1998) 79, 1461-1468.
			Wickham et al.; Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types; Nature Biotechnology, Volume 14, November 1996.
			Wickham et al.; Increased In Vitro and In Vivo Gene Transfer by Adenovirus Vectors Containing Chimeric Fiber Proteins; Journal of Virology, Nov. 1997, pp. 8221-8229.
			Yee et al.; Adenovirus-Mediated Gene Transfer of Herpes Simplex Virus Thymidine Kinase in an Ascites Model of Human Breast Cancer; Human Gene Therapy 7:1251-1257 (June 20, 1996).
			Zeng, Sticky-End PCR: New Method for Subcloning; BioTechniques, Vol. 25, No. 2 (1998), pp. 206-208.
			Zitvogel et al.; Therapy of Murine Tumors with Tumor Peptide-pulsed Dendritic Cells: Dependence on T Cells, B7 costimulation, and T Helper Cell 1-associated Cytokines; Journal Exp. Med. Volume 183 January 1996 87-97.
EXAMINER			DATE CONSIDERED
<p>* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			